Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Devine

Showing results (161-170 of 178) with videos related to

Pageof 18
Sort By:
JAMA Network Open|May 5, 2026
Hematopoietic Cell Transplant Access and Patient DiversityRachel Cusatis, Jianqun Kou, Caitrin Bupp, et al.
Transplantation and Cellular Therapy|April 21, 2022
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and OutcomesRachel Phelan, Min Chen, Caitrin Bupp, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
The Journal of Clinical Investigation|October 2, 2014
Ibrutinib treatment ameliorates murine chronic graft-versus-host diseaseJason A Dubovsky, Ryan Flynn, Jing Du, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Frontiers in Immunology|September 20, 2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 TrialPolina Shindiapina, Maciej Pietrzak, Michal Seweryn, et al.
Transplantation and Cellular Therapy|September 30, 2025
Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377Stephen R Spellman, Ke Xu, Temitope Oloyede, et al.
Blood Advances|November 21, 2025
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 StudyAndrew S Artz, Brent R Logan, Wael Saber, et al.
Transplantation and Cellular Therapy|June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research RegistryRachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.
Blood Advances|March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Pageof 18

Showing results (161-170 of 178) with videos related to

Sort By:
Pageof 18
JAMA Network Open|May 5, 2026
Hematopoietic Cell Transplant Access and Patient DiversityRachel Cusatis, Jianqun Kou, Caitrin Bupp, et al.
Transplantation and Cellular Therapy|April 21, 2022
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and OutcomesRachel Phelan, Min Chen, Caitrin Bupp, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
The Journal of Clinical Investigation|October 2, 2014
Ibrutinib treatment ameliorates murine chronic graft-versus-host diseaseJason A Dubovsky, Ryan Flynn, Jing Du, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Frontiers in Immunology|September 20, 2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 TrialPolina Shindiapina, Maciej Pietrzak, Michal Seweryn, et al.
Transplantation and Cellular Therapy|September 30, 2025
Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377Stephen R Spellman, Ke Xu, Temitope Oloyede, et al.
Blood Advances|November 21, 2025
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 StudyAndrew S Artz, Brent R Logan, Wael Saber, et al.
Transplantation and Cellular Therapy|June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research RegistryRachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.
Blood Advances|March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Pageof 18